PolyNovo (PNV) H1 2025 earnings summary

Executive summary

• Commercial sales increased 28% year-over-year, with patient impact up 72% and presence expanded to 46 countries, treating over 67,000 patients to date.

• NovoSorb MTX launched in the U.S., generating AUD 2.1 million in first-half revenue and expected to outpace BTM in 3–5 years.

• Strong market share gains in Europe (50% growth), continued U.S. leadership, and rapid expansion in India and Turkey.

• Ongoing investment in clinical evidence, health economics, sales, R&D, and manufacturing to support global adoption and new product launches.

• Employee headcount increased by 45 year-over-year, with 28 added in 1H25.

Financial highlights

• Total revenue reached AUD 59.9 million (USD 59.9m), up 22.8% year-over-year; NovoSorb product sales rose 28.2% to AUD 54.1 million.

• Net profit after tax was AUD 3.3 million, up 23.9%; operating profit reached AUD 5.7 million; EBITDA grew to AUD 7.2 million.

• Cash and cash equivalents at period end were AUD 30.5 million, down from AUD 45.9 million at June 2024.

• BARDA revenue contributed AUD 5.4 million, expected to taper off as clinical trial costs wind down.

• Order growth up 58%, units sold up 62% year-over-year.

Outlook and guidance

• Targeting 25% CAGR in coming years, with a focus on responsible, capital-efficient growth.

• U.S. remains primary growth market, with significant runway in trauma, plastics, and reconstructive surgery.

• MTX expected to become the leading platform product within 3–5 years; new product launches (MTX Thick, MTX Fill, Syntrel, Syntrix) planned through FY26.

• Expansion into Japan, China, and other emerging markets underway, leveraging clinical trial data for regulatory approvals.

• Capacity expansion with new Innovation Centre (June 2025) and third manufacturing site (Dec 2025).